Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma

Leukemia

Volumn 28, Issue 8, 2014, Pages 1705-1715

  Melchor, L ^a   Brioli, A ^a,b   Wardell, C P ^a   Murison, A ^a   Potter, N E ^a   Kaiser, M F ^a   Fryer, R A ^a   Johnson, D C ^a   Begum, D B ^a   Wilson, S Hulkki ^a   Vijayaraghavan, G ^a   Titley, I ^a   Cavo, M ^b   Davies, F E ^a   Walker, B A ^a   Morgan, G J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

exome sequencing; intraclonal heterogeneity; intratumor heterogeneity; multiple myeloma; parallel evolution; single cell analysis

Indexed keywords

AGED; ANIMALS; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 14; CLONAL EVOLUTION; FEMALE; GENES, RAS; HUMANS; INTERFERON REGULATORY FACTORS; MALE; MICE; MICE, SCID; MIDDLE AGED; MULTIPLE MYELOMA; MUTATION; PHYLOGENY; SELECTION, GENETIC; SINGLE-CELL ANALYSIS; TRANSLOCATION, GENETIC;

EID: 84905690692     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.13     Document Type: Article

References (46)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
2. Nowell PC. The clonal evolution of tumor cell populations. Science 1976; 194: 23-28.
3. Greaves M, Maley CC. Clonal evolution in cancer. Nature 2012; 481: 306-313.
4. Anderson K, Lutz C, van Delft FW, Bateman CM, Guo Y, Colman SM et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011; 469: 356-361.
5. Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E et al. Clonal competition with alternating dominance in multiple myeloma. Blood 2012; 120: 1067-1076.
6. Merlo LM, Pepper JW, Reid BJ, Maley CC. Cancer as an evolutionary and ecological process. Nat Rev Cancer 2006; 6: 924-935.
7. Sottoriva A, Spiteri I, Piccirillo SG, Touloumis A, Collins VP, Marioni JC et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci USA 2013; 110: 4009-4014.
8. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012; 481: 506-510.
9. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-892.
10. Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD, Lau KW et al. The life history of 21 breast cancers. Cell 2012; 149: 994-1007.
11. Walker BA, Wardell CP, Melchor L, Hulkki S, Potter NE, Johnson DC et al. Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4; 14) and t(11; 14) myeloma. Blood 2012; 120: 1077-1086.
12. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010; 467: 1109-1113.
13. Greaves M. Cancer stem cells as 'units of selection'. Evol Appl 2013; 6: 102-108.
14. Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest 2012; 122: 3456-3463.
15. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer 2012; 12: 335-348.
16. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471: 467-472.
17. Egan JB, Shi CX, Tembe W, Christoforides A, Kurdoglu A, Sinari S et al. Wholegenome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 2012; 120: 1060-1066.
18. Magrangeas F, Avet-Loiseau H, Gouraud W, Lode L, Decaux O, Godmer P et al. Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia 2013; 27: 473-481.
19. Durinck S, Ho C, Wang NJ, Liao W, Jakkula LR, Collisson EA et al. Temporal dissection of tumorigenesis in primary cancers. Cancer Discov 2011; 1: 137-143.
20. Potter NE, Ermini L, Papaemmanuil E, Cazzaniga G, Vijayaraghavan G, Titley I et al. Single-cell mutational profiling and clonal phylogeny in cancer. Genome Res 2013; 23: 2115-2125.
21. Boyd KD, Ross FM, Chiecchio L, Dagrada GP, Konn ZJ, Tapper WJ et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia 2012; 26: 349-355.
22. Chiecchio L, Protheroe RK, Ibrahim AH, Cheung KL, Rudduck C, Dagrada GP et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia 2006; 20: 1610-1617.
23. Walker BA, Wardell CP, Johnson DC, Kaiser MF, Begum DB, Dahir NB et al. Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. Blood 2013; 121: 3413-3419.
24. Walker BA, Leone PE, Chiecchio L, Dickens NJ, Jenner MW, Boyd KD et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood 2010; 116: e56-e65.
25. Walker BA, Leone PE, Jenner MW, Li C, Gonzalez D, Johnson DC et al. Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood 2006; 108: 1733-1743.
26. Weaver S, Dube S, Mir A, Qin J, Sun G, Ramakrishnan R et al. Taking qPCR to a higher level: analysis of CNV reveals the power of high throughput qPCR to enhance quantitative resolution. Methods 2010; 50: 271-276.
27. Sims D, Bursteinas B, Gao Q, Jain E, MacKay A, Mitsopoulos C et al. ROCK: a breast cancer functional genomics resource. Breast Cancer Res Treat 2010; 124: 567-572.
28. Fryer RA, Graham TJ, Smith EM, Walker-Samuel S, Morgan GJ, Robinson SP et al. Characterization of a novel mouse model of multiple myeloma and its use in preclinical therapeutic assessment. PLoS One 2013; 8: e57641.
29. Scrucca L. GA: A package for genetic algorithms in R. J Stat Softw 2013; 53: 1-37.
30. Fonseca R, Bailey RJ, Ahmann GJ, Rajkumar SV, Hoyer JD, Lust JA et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 2002; 100: 1417-1424.
31. Walker BA, Wardell CP, Melchor L, Brioli A, Johnson DC, Kaiser MF et al. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia 2014; 28: 384-390.
32. Park SY, Gonen M, Kim HJ, Michor F, Polyak K. Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest 2010; 120: 636-644.
33. Newburger DE, Kashef-Haghighi D, Weng Z, Salari R, Sweeney RT, Brunner AL et al. Genome evolution during progression to breast cancer. Genome Res 2013; 23: 1097-1108.
34. Merlo LM, Shah NA, Li X, Blount PL, Vaughan TL, Reid BJ et al. A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma. Cancer Prev Res (Phila) 2010; 3: 1388-1397.
35. Forrester K, Almoguera C, Han K, Grizzle WE, Perucho M. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature 1987; 327: 298-303.
36. Farr CJ, Saiki RK, Erlich HA, McCormick F, Marshall CJ. Analysis of RAS gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes. Proc Natl Acad Sci USA 1988; 85: 1629-1633.
37. Itzykson R, Kosmider O, Renneville A, Morabito M, Preudhomme C, Berthon C et al. Clonal architecture of chronic myelomonocytic leukemias. Blood 2013; 121: 2186-2198.
38. Andrulis M, Lehners N, Capper D, Penzel R, Heining C, Huellein J et al. Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov 2013; 3: 862-869.
39. Lu R. Interferon regulatory factor 4 and 8 in B-cell development. Trends Immunol 2008; 29: 487-492.
40. Lamy L, Ngo VN, Emre NC, Shaffer 3rd AL, Yang Y, Tian E et al. Control of autophagic cell death by caspase-10 in multiple myeloma. Cancer Cell 2013; 23: 435-449.
41. Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao W et al. IRF4 addiction in multiple myeloma. Nature 2008; 454: 226-231.
42. Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012; 26: 2326-2335.
43. Zhang LH, Kosek J, Wang M, Heise C, Schafer PH, Chopra R. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression. Br J Haematol 2013; 160: 487-502.
44. Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011; 118: 4771-4779.
45. Havelange V, Pekarsky Y, Nakamura T, Palamarchuk A, Alder H, Rassenti L et al. IRF4 mutations in chronic lymphocytic leukemia. Blood 2011; 118: 2827-2829.
46. Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res 2012; 72: 4875-4882.